Basic Stats
| CIK | 1946563 |
SEC Filings
All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis.
These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to 60 Degrees Pharmaceuticals, Inc.
SEC Filings (Chronological Order)
This page provides a complete, chronological list of SEC Filings, excluding ownership filings which we provide elsewhere.
| September 5, 2025 |
AT THE MARKET OFFERING AGREEMENT Exhibit 1.1 AT THE MARKET OFFERING AGREEMENT September 5, 2025 H.C. Wainwright & Co., LLC 430 Park Avenue New York, New York 10022 Ladies and Gentlemen: 60 Degrees Pharmaceuticals, Inc., a corporation organized under the laws of Delaware (the “Company”), confirms its agreement (this “Agreement”) with H.C. Wainwright & Co., LLC (the “Manager”) as follows: 1. Definitions. The terms that follow, when |
|
| September 5, 2025 |
Filed Pursuant to Rule 424(b)(5) Registration No. 333-280796 PROSPECTUS SUPPLEMENT (To Prospectus dated September July 12, 2024) Up to $1,397,532 Common Stock We have entered into an At The Market Offering Agreement (the “Sales Agreement”) with H.C. Wainwright & Co., LLC (the “Agent”) relating to shares of our common stock offered by this prospectus supplement and the accompanying base prospectu |
|
| September 5, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): September 3, 2025 60 DEGREES PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-41719 45-2406880 (State or other jurisdiction of Incorporation) |
|
| September 2, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 (Amendment No. 1 to) Schedule 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ D |
|
| August 27, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Definitive Proxy State |
|
| August 15, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a party other than the Registrant ☐ Check the appropriate box: ☒ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Definitive Proxy State |
|
| August 13, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 Form 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED June 30, 2025 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM to COMMISSION FILE NUMBER 001-41719 60 DEGREES |
|
| July 18, 2025 |
Form of Placement Agent Warrant Exhibit 4.4 PLACEMENT AGENT COMMON STOCK PURCHASE WARRANT 60 DEGREES PHARMACEUTICALS, INC. Warrant Shares: Issue Date: July 16, 2025 Initial Exercise Date: July 16, 2025 THIS PLACEMENT AGENT COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, [] or his assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions here |
|
| July 18, 2025 |
Form of Securities Purchase Agreement by and between the Company and the Investors Exhibit 10.1 SECURITIES PURCHASE AGREEMENT THIS SECURITIES PURCHASE AGREEMENT (this “Agreement”) is entered into and made effective as of [*], 2025, between 60 DEGREES PHARMACEUTICALS, INC., a Delaware corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively the “Purchasers”). RECITALS WHERE |
|
| July 18, 2025 |
Exhibit 4.3 PRE-FUNDED COMMON STOCK PURCHASE WARRANT 60 Degrees pharmaceuticals, inc. Warrant Shares: Issue Date: July 16, 2025 Initial Exercise Date: July 16, 2025 THIS PRE-FUNDED COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set f |
|
| July 18, 2025 |
Exhibit 4.1 SERIES A-1 COMMON STOCK PURCHASE WARRANT 60 Degrees pharmaceuticals, inc. Warrant Shares: Issue Date: July 16, 2025 Initial Exercise Date: July 16, 2025 THIS SERIES A-1 COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set f |
|
| July 18, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): July 15, 2025 60 DEGREES PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-41719 45-2406880 (State or other jurisdiction of Incorporation) (Com |
|
| July 18, 2025 |
60 Degrees Pharmaceuticals Announces Pricing of Up to $10 Million Public Offering Exhibit 99.1 60 Degrees Pharmaceuticals Announces Pricing of Up to $10 Million Public Offering $5 million upfront with up to an additional $5 million of potential aggregate gross proceeds upon the exercise in full of short-term warrants WASHINGTON, July 15, 2025 (GLOBE NEWSWIRE) - 60 Degrees Pharmaceuticals, Inc. (the “Company” or “60 Degrees”) (Nasdaq: SXTP; SXTPW), a pharmaceutical company focus |
|
| July 18, 2025 |
Exhibit 4.2 SERIES A-2 COMMON STOCK PURCHASE WARRANT 60 Degrees pharmaceuticals, inc. Warrant Shares: Issue Date: July 16, 2025 Initial Exercise Date: July 16, 2025 THIS SERIES A-2 COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set f |
|
| July 18, 2025 |
Exhibit 99.2 60 Degrees Pharmaceuticals Announces Closing of up to $10 Million Public Offering $5 million received upfront with up to an additional $5 million of potential aggregate gross proceeds upon the exercise in full of short-term warrants WASHINGTON / GLOBE NEWSWIRE / July 16, 2025 / 60 Degrees Pharmaceuticals, Inc. (the “Company” or “60 Degrees”) (Nasdaq: SXTP; SXTPW), a pharmaceutical com |
|
| July 16, 2025 |
Filed pursuant to Rule 424(b)(4) Registration No. 333-288550 1,753,314 Shares of Common Stock Series A-1 Warrants to Purchase up to 1,753,314 Shares of Common Stock Series A-2 Warrants to Purchase up to 1,753,314 Shares of Common Stock 878,264 Pre-Funded Warrants to Purchase up to 878,264 Shares of Common Stock Series A-1 Warrants to Purchase up to 878,264 Shares of Common Stock Series A-2 Warrant |
|
| July 10, 2025 |
July 10, 2025 VIA EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street NE Washington, D.C. 20549 Attention: Chris Edwards Re: 60 Degrees Pharmaceuticals, Inc. Registration Statement on Form S-1 File No. 333-288550 Filed July 7, 2025 Ladies and Gentlemen: 60 Degrees Pharmaceuticals, Inc. (the “Company”) hereby requests acceleration of the effective date of the |
|
| July 10, 2025 |
July 10, 2025 VIA EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street NE Washington, D.C. 20549 Re: 60 Degrees Pharmaceuticals, Inc. Registration Statement on Form S-1 File No. 333-288550 Ladies and Gentlemen: In accordance with Rule 461 under the Securities Act of 1933, as amended (the “Securities Act”), H.C. Wainwright & Co., LLC (“Wainwright”), as placemen |
|
| July 7, 2025 |
Form of Series A-1/A-2 Warrant Exhibit 4.1 SERIES [A-1][A-2] COMMON STOCK PURCHASE WARRANT 60 Degrees pharmaceuticals, inc. Warrant Shares: Issue Date:, 2025 Initial Exercise Date: , 2025 THIS SERIES [A-1] [A-2] COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set f |
|
| July 7, 2025 |
Exhibit 4.2 PRE-FUNDED COMMON STOCK PURCHASE WARRANT 60 DEGREES PHARMACEUTICALS, INC. Warrant Shares: Issue Date:, 2025 Initial Exercise Date: , 2025 THIS PRE-FUNDED COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any ti |
|
| July 7, 2025 |
Form of Securities Purchase Agreement Exhibit 10.14 SECURITIES PURCHASE AGREEMENT THIS SECURITIES PURCHASE AGREEMENT (this “Agreement”) is entered into and made effective as of [*], 2025, between 60 DEGREES PHARMACEUTICALS, INC., a Delaware corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively the “Purchasers”). RECITALS WHER |
|
| July 7, 2025 |
As filed with the U.S. Securities and Exchange Commission on July 7, 2025. As filed with the U.S. Securities and Exchange Commission on July 7, 2025. Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 60 DEGREES PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 2834 45-2406880 (State or Other Jurisdiction of Incorporation or Orga |
|
| July 7, 2025 |
Exhibit 107 Calculation of Filing Fee Tables Form S-1 60 Degrees Pharmaceuticals, Inc. |
|
| July 7, 2025 |
Form of Placement Agent Warrant Exhibit 4.3 PLACEMENT AGENT COMMON STOCK PURCHASE WARRANT 60 DEGREES PHARMACEUTICALS, INC. Warrant Shares: Issue Date:, 2025 Initial Exercise Date: , 2025 THIS PLACEMENT AGENT COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, |
|
| June 6, 2025 |
As confidentially submitted to the U.S. Securities and Exchange Commission on June 6, 2025. This draft registration statement has not been publicly filed with the Securities and Exchange Commission and all information herein remains strictly confidential. Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITI |
|
| May 15, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 Form 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED MARCH 31, 2025 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM to COMMISSION FILE NUMBER 001-41719 60 DEGREES |
|
| April 9, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): April 4, 2025 60 DEGREES PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-41719 45-2406880 (State or other jurisdiction of Incorporation) (Com |
|
| March 31, 2025 |
60 DEGREES PHARMACEUTICALS, INC. 1025 Connecticut Avenue NW Suite 1000 Washington, D.C. 20036 60 DEGREES PHARMACEUTICALS, INC. 1025 Connecticut Avenue NW Suite 1000 Washington, D.C. 20036 March 31, 2025 VIA EDGAR United States Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences 100 F Street, N.E. Washington, D.C. 20549 Re: 60 Degrees Pharmaceuticals, Inc. Acceleration Request for Registration Statement on Form S-1 File No. 333-284983 Requested Date: A |
|
| March 27, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Fiscal Year Ended December 31, 2024 ☐ TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from until Commission File Number: 001-41719 60 DEGREES PHARMACEUTICALS, INC. (Exa |
|
| March 27, 2025 |
Exhibit 107 Ex-Filing Fees CALCULATION OF FILING FEE TABLE FORM S-1 (Form Type) 60 Degrees Pharmaceuticals, Inc. |
|
| March 27, 2025 |
As filed with the U.S. Securities and Exchange Commission on March 27, 2025. As filed with the U.S. Securities and Exchange Commission on March 27, 2025. Registration No. 333-284983 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 AMENDMENT NO. 1 TO FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 60 DEGREES PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 2834 45-2406880 (State or Other Jurisdicti |
|
| March 27, 2025 |
Exhibit 19.1 60 DEGREES PHARMACEUTICALS, INC. INSIDER TRADING POLICY Purpose This Insider Trading Policy (this “Policy”) provides guidelines with respect to transactions in the securities of 60 Degrees Pharmaceuticals, Inc., a Delaware corporation (the “Company”), and the handling of confidential information about the Company and the companies with which the Company does business. The Company’s Bo |
|
| February 14, 2025 |
As filed with the U.S. Securities and Exchange Commission on February 14, 2025. As filed with the U.S. Securities and Exchange Commission on February 14, 2025. Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 60 DEGREES PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 2834 45-2406880 (State or Other Jurisdiction of Incorporation or |
|
| February 14, 2025 |
Exhibit 107 Ex-Filing Fees CALCULATION OF FILING FEE TABLE FORM S-1 (Form Type) 60 Degrees Pharmaceuticals, Inc. |
|
| February 11, 2025 |
Exhibit 1 JOINT FILING AGREEMENT The undersigned acknowledge and agree that the foregoing statement on Schedule 13G is filed on behalf of each of the undersigned and that all subsequent amendments to this statement on Schedule 13G may be filed on behalf of each of the undersigned without the necessity of filing additional joint filing agreements. |
|
| February 6, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): February 5, 2025 60 DEGREES PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-41719 45-2406880 (State or other jurisdiction of Incorporation) ( |
|
| February 6, 2025 |
Exhibit 99.1 60 Degrees Pharma Announces $1.075 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules WASHINGTON, Feb. 05, 2025 (GLOBE NEWSWIRE) - 60 Degrees Pharmaceuticals, Inc. (NASDAQ: SXTP; SXTPW) (the “Company”), a pharmaceutical company focused on developing new medicines for infectious diseases, today announced that it has entered into definitive agreements for the pur |
|
| February 6, 2025 |
1,503,500 Shares of Common Stock 60 Degrees Pharmaceuticals, Inc. Filed Pursuant to Rule 424(b)(5) Registration No. 333-280796 PROSPECTUS SUPPLEMENT (To Prospectus dated July 12, 2024) 1,503,500 Shares of Common Stock 60 Degrees Pharmaceuticals, Inc. We are offering 1,503,500 shares of our common stock, par value $0.0001 per share, directly to certain institutional investors pursuant to this prospectus supplement and the accompanying prospectus. The offering pri |
|
| February 6, 2025 |
Exhibit 4.2 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTR |
|
| February 6, 2025 |
Exhibit 10.1 SECURITIES PURCHASE AGREEMENT THIS SECURITIES PURCHASE AGREEMENT (this “Agreement”) is entered into and made effective as of February 5, 2025, between 60 DEGREES PHARMACEUTICALS, INC., a Delaware corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively the “Purchasers”). RECITAL |
|
| February 6, 2025 |
Exhibit 4.1 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTR |
|
| February 6, 2025 |
Exhibit 99.2 60 Degrees Pharma Announces Closing of $1.075 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules Raised approximately $2.118 million in gross proceeds since the beginning of 2025 WASHINGTON, D.C., February 6, 2025 - 60 Degrees Pharmaceuticals, Inc. (NASDAQ: SXTP; SXTPW) (the “Company”), a pharmaceutical company focused on developing new medicines for infectious |
|
| February 3, 2025 |
Exhibit 1 JOINT FILING AGREEMENT The undersigned acknowledge and agree that the foregoing statement on Schedule 13G is filed on behalf of each of the undersigned and that all subsequent amendments to this statement on Schedule 13G may be filed on behalf of each of the undersigned without the necessity of filing additional joint filing agreements. |
|
| January 30, 2025 |
1,021,549 Shares of Common Stock 60 Degrees Pharmaceuticals, Inc. Filed Pursuant to Rule 424(b)(5) Registration No. 333-280796 PROSPECTUS SUPPLEMENT (To Prospectus dated July 12, 2024) 1,021,549 Shares of Common Stock 60 Degrees Pharmaceuticals, Inc. We are offering 1,021,549 shares of our common stock, par value $0.0001 per share, directly to certain institutional investors pursuant to this prospectus supplement and the accompanying prospectus. The offering pri |
|
| January 30, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): January 28, 2025 60 DEGREES PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-41719 45-2406880 (State or other jurisdiction of Incorporation) ( |
|
| January 30, 2025 |
Exhibit 10.1 SECURITIES PURCHASE AGREEMENT THIS SECURITIES PURCHASE AGREEMENT (this “Agreement”) is entered into and made effective as of January 28, 2025, between 60 DEGREES PHARMACEUTICALS, INC., a Delaware corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively the “Purchasers”). RECITAL |
|
| January 30, 2025 |
Exhibit 1.1 August 30, 2024 STRICTLY CONFIDENTIAL 60 Degrees Pharmaceuticals, Inc. 1025 Connecticut Avenue NW Suite 1000, Washington, D.C. 20036 Attn: Geoffrey Dow, Chief Executive Officer and President Dear Mr. Dow: This letter agreement (this “Agreement”) constitutes the agreement between 60 Degrees Pharmaceuticals, Inc. (the “Company”) and H.C. Wainwright & Co., LLC (“Wainwright”), that Wainwri |
|
| January 30, 2025 |
Exhibit 4.1 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTR |
|
| January 30, 2025 |
Exhibit 1.3 Execution Version January [], 2025 STRICTLY CONFIDENTIAL 60 Degrees Pharmaceuticals, Inc. 1025 Connecticut Avenue NW, Suite 1000, Washington, D.C. 20036 Attn: Geoffrey Dow, Chief Executive Officer and President Dear Mr. Dow: Reference is made to that certain engagement agreement (the “Engagement Agreement”), dated as of August 30, 2024, as amended on September 3, 2024, by and between 6 |
|
| January 30, 2025 |
Exhibit 99.2 60 Degrees Pharma Announces Closing of $1.043 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules WASHINGTON, D.C., January 30, 2025 - 60 Degrees Pharmaceuticals, Inc. (NASDAQ: SXTP; SXTPW) (the “Company”), a pharmaceutical company focused on developing new medicines for infectious diseases, today announced the closing of its previously announced registered dire |
|
| January 30, 2025 |
Exhibit 4.2 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTR |
|
| January 30, 2025 |
Exhibit 1.2 Execution Version September 3, 2024 STRICTLY CONFIDENTIAL 60 Degrees Pharmaceuticals, Inc. 1025 Connecticut Avenue NW Suite 1000, Washington, D.C. 20036 Attn: Geoffrey Dow, Chief Executive Officer and President Dear Mr. Dow: Reference is made to the engagement letter (the “Engagement Letter”), dated as of August 30, 2024, by between 60 Degrees Pharmaceuticals, Inc. (the “Company”) and |
|
| January 30, 2025 |
Exhibit 99.1 60 Degrees Pharma Announces $1.043 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules WASHINGTON, Jan. 29, 2025 (GLOBE NEWSWIRE) - 60 Degrees Pharmaceuticals, Inc. (NASDAQ: SXTP; SXTPW) (the “Company”), a pharmaceutical company focused on developing new medicines for infectious diseases, today announced that it has entered into definitive agreements for the pur |
|
| January 28, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): January 28, 2025 60 DEGREES PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-41719 45-2406880 (State or other jurisdiction of Incorporation) ( |
|
| January 28, 2025 |
Exhibit 99.1 60 Degrees Pharma Announces IRB Approval of Phase II Study to Evaluate Tafenoquine for Chronic Babesiosis ● Investigational Review Board (IRB) approval has been granted for the open-label study to evaluate tafenoquine for treatment of patients with a presumptive diagnosis of chronic babesiosis in outpatient settings. ● Enrollment expected to commence Q3 2025. WASHINGTON, D.C., January |
|
| January 8, 2025 |
Exhibit 99.1 60 Degrees Pharmaceuticals Enrolls First Patient in Tafenoquine Expanded Access Clinical Study for Persistent (B. microti) Babesiosis ● Case reports published in medical literature suggest that tafenoquine combined with standard-of-care treatment exhibits a high cure rate in immunosuppressed patients who have relapsing babesiosis and for whom prior treatment has failed. ● Babesiosis, |
|
| January 8, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): January 8, 2025 60 DEGREES PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-41719 45-2406880 (State or other jurisdiction of Incorporation) (C |
|
| November 14, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 Form 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED SEPTEMBER 30, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM to COMMISSION FILE NUMBER 001-41719 60 DEG |
|
| November 14, 2024 |
SXTP / 60 Degrees Pharmaceuticals, Inc. / ARMISTICE CAPITAL, LLC Passive Investment SC 13G 1 armistice-sxtp093024.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* 60 DEGREES PHARMACEUTICALS, INC. (Name of Issuer) Common Stock, par value $0.0001 (Title of Class of Securities) 83006G203 (CUSIP Number) September 30, 2024 (Date of Event Which Requires Filing of this Statement) Check the |
|
| November 13, 2024 |
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G/A (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO § 240.13d-1(b), (c) AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO § 240.13d-2 UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. 2)* 60 Degrees Pharmaceuticals, Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of |
|
| November 6, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): November 6, 2024 60 DEGREES PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-41719 45-2406880 (State or other jurisdiction of Incorporation) ( |
|
| October 15, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Defin |
|
| October 8, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): October 2, 2024 60 DEGREES PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-41719 45-2406880 (State or other jurisdiction of Incorporation) (C |
|
| October 8, 2024 |
Exhibit 99.1 60 Degrees Pharmaceuticals Inc. Announces ARAKODA® Promotional Pilot in Advance of Expanded U.S. Launch ● Highlights include increased ARAKODA® (tafenoquine) brand awareness and utilization through virtual sales outreach using digital behavioral analytics and a co-pay program to assist consumers with out-of-pocket costs. ● ARAKODA is the only new antimalarial in over a decade and is d |
|
| October 2, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☒ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Defin |
|
| September 26, 2024 |
60 DEGREES PHARMACEUTICALS, INC. 1025 Connecticut Avenue NW Suite 1000 Washington, D.C. 20036 60 DEGREES PHARMACEUTICALS, INC. 1025 Connecticut Avenue NW Suite 1000 Washington, D.C. 20036 September 26, 2024 VIA EDGAR United States Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences 100 F Street, N.E. Washington, D.C. 20549 Attention: Mr. Alan Campbell Re: 60 Degrees Pharmaceuticals, Inc. Acceleration Request for Registration Statement on Form S-3 File |
|
| September 19, 2024 |
Exhibit 107 Calculation of Filing Fee Table Form S-3 (Form Type) 60 Degrees Pharmaceuticals, Inc. |
|
| September 19, 2024 |
Exhibit 10.2 Specific information contained in this agreement has been excluded due to its non-material nature and because such information is considered private or confidential. Upon the request by Commission or its staff, the Company will quickly provide an unredacted copy of this agreement, along with analyses supporting its decisions on materiality and confidentiality. CLINICAL TRIAL AGREEMENT |
|
| September 19, 2024 |
Exhibit 10.3 Specific information contained in this agreement has been excluded due to its non-material nature and because such information is considered private or confidential. Upon the request by Commission or its staff, the Company will quickly provide an unredacted copy of this agreement, along with analyses supporting its decisions on materiality and confidentiality. CLINICAL TRIAL AGREEMENT |
|
| September 19, 2024 |
As filed with the Securities and Exchange Commission on September 19, 2024 As filed with the Securities and Exchange Commission on September 19, 2024 Registration No. |
|
| September 6, 2024 |
Exhibit 10.4 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGIST |
|
| September 6, 2024 |
Exhibit 10.3 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGIST |
|
| September 6, 2024 |
Form of Securities Purchase Agreement Exhibit 10.1 SECURITIES PURCHASE AGREEMENT THIS SECURITIES PURCHASE AGREEMENT (this “Agreement”) is entered into and made effective as of September 4, 2024, between 60 DEGREES PHARMACEUTICALS, INC., a Delaware corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively the “Purchasers”). RECITA |
|
| September 6, 2024 |
Exhibit 10.5 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGIST |
|
| September 6, 2024 |
Exhibit 99.1 60 Degrees Pharmaceuticals, Inc. Announces $4 Million Private Placement Priced At-the-Market Under Nasdaq Rules WASHINGTON, Sept. 04, 2024 (GLOBE NEWSWIRE) - 60 Degrees Pharmaceuticals, Inc. (NASDAQ: SXTP; SXTPW) (“60P” or the “Company”), a pharmaceutical company focused on developing new medicines for infectious diseases, today announced that it has entered into definitive agreements |
|
| September 6, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): September 4, 2024 60 DEGREES PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-41719 45-2406880 (State or other jurisdiction of Incorporation) |
|
| September 6, 2024 |
Form of Registration Rights Agreement Exhibit 10.2 REGISTRATION RIGHTS AGREEMENT THIS REGISTRATION RIGHTS AGREEMENT (this “Agreement”) is entered into and made effective as of September 4, 2024, by and between 60 DEGREES PHARMACEUTICALS, INC., a Delaware corporation (the “Company”), and each of the several purchasers signatory hereto (each such purchaser, a “Purchaser” and, collectively, the “Purchasers”). This Agreement is made pursu |
|
| September 6, 2024 |
Form of Placement Agent Warrant Exhibit 10.6 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGIST |
|
| September 6, 2024 |
Exhibit 99.2 60 Degrees Pharmaceuticals, Inc. Announces Closing of $4 Million Private Placement Priced At-the-Market Under Nasdaq Rules WASHINGTON, Sep. 6, 2024 (GLOBE NEWSWIRE) - 60 Degrees Pharmaceuticals, Inc. (NASDAQ: SXTP; SXTPW) (“60P” or the “Company”), a pharmaceutical company focused on developing new medicines for infectious diseases, today announced the closing of its previously announc |
|
| August 28, 2024 |
60 Degrees Pharmaceuticals, Inc. Regains Compliance with Nasdaq Listing Requirements Exhibit 99.1 60 Degrees Pharmaceuticals, Inc. Regains Compliance with Nasdaq Listing Requirements WASHINGTON, Aug. 28, 2024 (GLOBE NEWSWIRE) - 60 Degrees Pharmaceuticals, Inc. (NASDAQ: SXTP; SXTPW) (“60P” or the “Company”), a pharmaceutical company focused on developing new medicines for infectious diseases, announced today that on August 26, 2024 it received written notice from the Listing Qualif |
|
| August 28, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): August 26, 2024 60 DEGREES PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-41719 45-2406880 (State or other jurisdiction of Incorporation) (C |
|
| August 14, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): August 12, 2024 60 DEGREES PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-41719 45-2406880 (State or other jurisdiction of Incorporation) (C |
|
| August 14, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 Form 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED JUNE 30, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM to COMMISSION FILE NUMBER 001-41719 60 DEGREES |
|
| August 14, 2024 |
Exhibit 99.1 60 Degrees Pharma Provides University of Kentucky with Right of Reference to ARAKODA® NDA in Support of SJ733 Phase IIb Study Published Aug 12, 2024 9:12am EDT 1. University of Kentucky will commence a Phase IIb clinical study of drug development candidate SJ733 for treatment of vivax malaria. 2. SJ733 will be combined with a single dose of tafenoquine in the study. 3. The right of re |
|
| August 12, 2024 |
60 Degrees Pharmaceuticals, Inc. Announces 1:12 Reverse Stock Split EXHIBIT 99.1 60 Degrees Pharmaceuticals, Inc. Announces 1:12 Reverse Stock Split Published Aug 6, 2024 9:26am EDT WASHINGTON, Aug. 06, 2024 (GLOBE NEWSWIRE) - 60 Degrees Pharmaceuticals, Inc. (NASDAQ: SXTP; SXTPW) (the “Company”), a pharmaceutical company focused on developing new medicines for infectious diseases, announced today that it will effect a 1-for-12 reverse stock split (“Reverse Stock |
|
| August 12, 2024 |
Exhibit 3.1 STATE OF DELAWARE CERTIFICATE OF AMENDMENT OF CERTIFICATE OF INCORPORATION (Pursuant to Section 242 of the General Corporation Law of the State of Delaware) 60 Degrees Pharmaceuticals, Inc., a corporation organized and existing under and by virtue of the General Corporation Law of the State of Delaware, does hereby certify: FIRST: That at a meeting of the Board of Directors of 60 Degre |
|
| August 12, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): August 12, 2024 60 DEGREES PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-41719 45-2406880 (State or other jurisdiction of Incorporation) (C |
|
| August 2, 2024 |
Up to $2,295,192 Common Stock 60 Degrees Pharmaceuticals, Inc. Filed Pursuant to Rule 424(b)(5) Registration No. 333-280796 PROSPECTUS SUPPLEMENT No. 4 (To the Prospectus and Prospectus Supplement dated July 12, 2024) Up to $2,295,192 Common Stock 60 Degrees Pharmaceuticals, Inc. We have entered into an At the Market Issuance Sales Agreement (the “Sales Agreement”) with WallachBeth Capital LLC (“WallachBeth”) relating to shares of our common stock offered by |
|
| July 26, 2024 |
Up to $2,190,416 Common Stock 60 Degrees Pharmaceuticals, Inc. Filed Pursuant to Rule 424(b)(5) Registration No. 333-280796 PROSPECTUS SUPPLEMENT No. 3 (To the Prospectus and Prospectus Supplement dated July 12, 2024) Up to $2,190,416 Common Stock 60 Degrees Pharmaceuticals, Inc. We have entered into an At the Market Issuance Sales Agreement (the “Sales Agreement”) with WallachBeth Capital LLC (“WallachBeth”) relating to shares of our common stock offered by |
|
| July 26, 2024 |
Exhibit 99.1 60 Degrees Pharmaceuticals Awarded Contract with U.S. Army for ARAKODA® Supply Chain Upgrade Support · 60 Degrees Pharmaceuticals has been awarded a contract with the United States Army Medical Materiel Development Activity to facilitate commercial validation of new bottle and replacement blister packaging of ARAKODA® (tafenoquine), the Company’s FDA-approved product indicated for mal |
|
| July 26, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): July 25, 2024 60 DEGREES PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-41719 45-2406880 (State or other jurisdiction of Incorporation) (Com |
|
| July 24, 2024 |
Up to $1,890,705 Common Stock 60 Degrees Pharmaceuticals, Inc. Filed Pursuant to Rule 424(b)(5) Registration No. 333-280796 PROSPECTUS SUPPLEMENT No. 2 (To the Prospectus and Prospectus Supplement dated July 12, 2024) Up to $1,890,705 Common Stock 60 Degrees Pharmaceuticals, Inc. We have entered into an At the Market Issuance Sales Agreement (the “Sales Agreement”) with WallachBeth Capital LLC (“WallachBeth”) relating to shares of our common stock offered by |
|
| July 22, 2024 |
Up to $1,774,640 Common Stock 60 Degrees Pharmaceuticals, Inc. Filed Pursuant to Rule 424(b)(5) Registration No. 333-280796 PROSPECTUS SUPPLEMENT No. 1 (To the Prospectus and Prospectus Supplement dated July 12, 2024) Up to $1,774,640 Common Stock 60 Degrees Pharmaceuticals, Inc. We have entered into an At the Market Issuance Sales Agreement (the “Sales Agreement”) with WallachBeth Capital LLC (“WallachBeth”) relating to shares of our common stock offered by |
|
| July 16, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): July 16, 2024 60 DEGREES PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-41719 45-2406880 (State or other jurisdiction of Incorporation) (Com |
|
| July 16, 2024 |
60 Degrees Pharmaceuticals, Inc. 1025 Connecticut Avenue NW, Suite 1000 Washington, DC 20036 60 Degrees Pharmaceuticals, Inc. 1025 Connecticut Avenue NW, Suite 1000 Washington, DC 20036 July 16, 2024 VIA EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Re: 60 Degrees Pharmaceuticals, Inc. Request for Acceleration Registration Statement on Form S-3 File No. 333-280796 Ladies and Gentlemen: Pursuant to Rule 461 promulgat |
|
| July 12, 2024 |
As filed with the Securities and Exchange Commission on July 12, 2024 As filed with the Securities and Exchange Commission on July 12, 2024 Registration No. |
|
| July 12, 2024 |
Exhibit 4.2 60 DEGREES PHARMACEUTICALS, INC. as the Company and as Trustee Senior Indenture Dated as of , 20 TABLE OF CONTENTS PAGE ARTICLE 1 DEFINITIONS AND INCORPORATION BY REFERENCE 1 Section 1.01. Definitions 1 Section 1.02. Other Definitions 5 Section 1.03. Incorporation by Reference of Trust Indenture Act 5 Section 1.04. Rules of Construction 6 ARTICLE 2 THE SECURITIES 6 Section 2.01. Form a |
|
| July 12, 2024 |
Form of Subordinated Indenture. Exhibit 4.3 60 DEGREES PHARMACEUTICALS, INC. as the Company and as Trustee Subordinated Indenture Dated as of , 20 TABLE OF CONTENTS PAGE ARTICLE 1 DEFINITIONS AND INCORPORATION BY REFERENCE 1 Section 1.01. Definitions 1 Section 1.02. Other Definitions 5 Section 1.03. Incorporation by Reference of Trust Indenture Act 5 Section 1.04. Rules of Construction 6 ARTICLE 2 THE SECURITIES 6 Section 2.01. |
|
| July 12, 2024 |
Filing Fee Table (filed herewith). Exhibit 107 Calculation of Filing Fee Table Form S-3 (Form Type) 60 Degrees Pharmaceuticals, Inc. |
|
| July 12, 2024 |
Exhibit 10.1 SPONSORED PROJECT AGREEMENT Sponsor Agreement Number (if any): N/A NC State RED Number: PAM-P24-003709 This Sponsored Project Agreement is entered into by and between North Carolina State University, Raleigh North Carolina (hereinafter called “University”), and 60 Degrees Pharmaceuticals INC with a principal place of business at 1025 Connecticut Avenue NW Suite 1000, Washington DC, 20 |
|
| July 12, 2024 |
Exhibit 10.3 CERTAIN APPENDIXES HAVE BEEN OMITTED PURSUANT TO ITEM 601(a)(5) OF REGULATION S-K. THE COMPANY AGREES TO FILE SUPPLEMENTALLY TO THE COMMISSION A COPY OF ANY OMITTED APPENDIX, UPON REQUEST. OMITTED APPENDIXES ARE REPRESENTED BY A [*]. CLINICAL TRIAL AGREEMENT PROTOCOL NUMBER: TQ-BA-2024-1 (NCT06207370) PROTOCOL TITLE: “Double-blind Placebo-controlled Study to Assess the Safety and Effi |
|
| July 12, 2024 |
Exhibit 1.1 60 Degrees Pharmaceuticals, Inc. Common Stock (par value $0.0001 per share) At-The-Market Issuance Sales Agreement June 4, 2024 WallachBeth Capital LLC 185 Hudson St Jersey City, NJ 07302 Ladies and Gentlemen: 60 Degrees Pharmaceuticals, Inc., a Delaware corporation (the “Company”), confirms its agreement (this “Agreement”) with WallachBeth Capital LLC (the “Agent”), as follows: 1. Iss |
|
| July 12, 2024 |
Exhibit 10.2 CERTAIN APPENDIXES HAVE BEEN OMITTED PURSUANT TO ITEM 601(a)(5) OF REGULATION S-K. THE COMPANY AGREES TO FILE SUPPLEMENTALLY TO THE COMMISSION A COPY OF ANY OMITTED APPENDIX, UPON REQUEST. OMITTED APPENDIXES ARE REPRESENTED BY A [*]. VETERINARY TRIAL AGREEMENT Sponsor Agreement Number (if any): Not applicable NC State RED Number: PAM-P24-003176 This Veterinary Trial Agreement (“Agreem |
|
| July 9, 2024 |
Exhibit 99.1 60 Degrees Pharma Announces IRB Approval of Clinical Study of Tafenoquine for Treatment of Babesiosis in Immunocompromised Patients with Persistent Babesia microti Despite Prior Treatment WASHINGTON, D.C., July 9, 2024 - 60 Degrees Pharmaceuticals, Inc. (NASDAQ: SXTP; SXTPW) (“60 Degrees Pharmaceuticals” or the “Company”), a pharmaceutical company focused on developing new medicines f |
|
| July 9, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): July 9, 2024 60 DEGREES PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-41719 45-2406880 (State or other jurisdiction of Incorporation) (Comm |
|
| June 27, 2024 |
Exhibit 99.1 First Patient Enrolled in 60 Degrees Pharmaceuticals Clinical Trial of Tafenoquine for Babesiosis at Tufts Medical Center; First and Only Study of Its Kind • The efficacy and safety of tafenoquine in treating human babesiosis will be evaluated in a randomized, double-blind, placebo-controlled trial conducted at Tufts Medical Center in Boston. • Endpoints are time to sustained clinical |
|
| June 27, 2024 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): June 27, 2024 60 DEGREES PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-41719 45-2406880 (State or other jurisdiction of Incorporation) (Com |
|
| June 12, 2024 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): June 11, 2024 60 DEGREES PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-41719 45-2406880 (State or other jurisdiction of Incorporation) (Com |
|
| June 12, 2024 |
Exhibit 99.1 60 Degrees Pharmaceuticals Receives FDA Orphan Drug Designation for Tafenoquine for Treatment of Patients with Acute Babesiosis · With the tafenoquine for acute babesiosis orphan drug designation, 60 Degrees Pharmaceuticals now qualifies for certain incentives, including market exclusivity, tax credits, and exemption from certain FDA filing fees. · 60 Degrees Pharmaceuticals recently |
|
| May 30, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Defin |
|
| May 15, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 Form 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED MARCH 31, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM to COMMISSION FILE NUMBER 001-41719 60 DEGREES |
|
| May 7, 2024 |
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G/A (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO § 240.13d-1(b), (c) AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO § 240.13d-2 UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. 1)* (Name of Issuer) 60 Degrees Pharmaceuticals, Inc. Common Stock, par value $0.0001 per share (Title of Class of |
|
| May 3, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☒ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Defin |
|
| May 2, 2024 |
Other Events, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): April 26, 2024 60 DEGREES PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-41719 45-2406880 (State or other jurisdiction of Incorporation) (Co |
|
| May 2, 2024 |
Exhibit 99.1 60 Degrees Pharmaceuticals Receives FDA Comments on Tafenoquine-Babesiosis Clinical Trial Protocol; No Material Changes Required ● Trial planning and execution to proceed as planned WASHINGTON, D.C., May 2, 2024 - 60 Degrees Pharmaceuticals, Inc. (NASDAQ: SXTP; SXTPW) (the “Company”), a pharmaceutical company focused on developing new medicines for infectious diseases, announced today |
|
| April 1, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Fiscal Year Ended December 31, 2023 ☐ TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from until Commission File Number: 001-41719 60 DEGREES PHARMACEUTICALS, INC. (Exa |
|
| April 1, 2024 |
Description of the Registrants' Securities Exhibit 4.1 DESCRIPTION OF REGISTRANT’S SECURITIES REGISTERED UNDER SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED The following description sets forth certain material terms and provisions of the common stock and warrants of 60 Degrees Pharmaceuticals, Inc., a Delaware corporation which are registered under Section 12(b) of the Securities Exchange Act of 1934, as amended (the “Exch |
|
| April 1, 2024 |
Exhibit 97.1 60 DEGREES PHARMACEUTICALS, INC. CLAWBACK POLICY Introduction The Board of Directors (“Board”) of 60 Degrees Pharmaceuticals, Inc. (the “Company”) believes that it is in the best interests of the Company and its stockholders to adopt this policy which provides for the recoupment of certain executive compensation in the event of an accounting restatement resulting from material noncomp |
|
| March 15, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): March 15, 2024 60 DEGREES PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-41719 45-2406880 (State or other jurisdiction of Incorporation) (Co |
|
| March 15, 2024 |
Exhibit 99.1 60 Degrees Pharmaceuticals Announces Communication from the FDA of Intention to Respond to Tafenoquine-Babesiosis Trial Protocol Submission in April, 2024 Washington, D.C., March 14, 2024 - 60 Degrees Pharmaceuticals, Inc., (NASDAQ: SXTP, SXTPW) (“60 Degrees Pharmaceuticals” or the “Company”), a pharmaceutical company focused on developing new medicines for infectious diseases, today |
|
| February 28, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): February 27, 2024 60 DEGREES PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-41719 45-2406880 (State or other jurisdiction of Incorporation) |
|
| February 20, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): February 13, 2024 60 DEGREES PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-41719 45-2406880 (State or other jurisdiction of Incorporation) |
|
| February 20, 2024 |
Exhibit 99.1 60 Degrees Pharmaceuticals to Sponsor Pre-Clinical Studies of Tafenoquine Use in Candida spp, Including Candida auris ● Candida auris (C. auris) is a dangerous drug-resistant fungal pathogen emerging in U.S. hospitals ● Tafenoquine’s presumed mode of action against C. auris is differentiated from standard of care treatment ● Monash University will conduct the studies beginning in seco |
|
| February 2, 2024 |
Exhibit 4.2 PRE-FUNDED COMMON STOCK PURCHASE WARRANT 60 DEGREES PHARMACEUTICALS, Inc. Warrant Shares: [●] Initial Exercise Date: [●] CUSIP: [●] Issue Date: [●] THIS PRE-FUNDED COMMON STOCK PURCHASE WARRANT (“Warrant”) certifies that, for value received, [●] or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, |
|
| February 2, 2024 |
Exhibit 4.4 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933 (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTRATION STATEM |
|
| February 2, 2024 |
60 Degrees Pharmaceuticals Announces Closing of $2.4 Million Public Offering Exhibit 99.2 60 Degrees Pharmaceuticals Announces Closing of $2.4 Million Public Offering WASHINGTON, Jan. 31, 2024 (GLOBE NEWSWIRE) — 60 Degrees Pharmaceuticals, Inc. (NASDAQ: SXTP; SXTPW) (“60 Degrees Pharmaceuticals” or the “Company”), specialists in developing and marketing new medicines for the treatment and prevention of infectious diseases, announced today the closing of its public offering |
|
| February 2, 2024 |
60 Degrees Pharmaceuticals Announces Pricing of $2.4 Million Public Offering Exhibit 99.1 60 Degrees Pharmaceuticals Announces Pricing of $2.4 Million Public Offering WASHINGTON, Jan. 30, 2024 (GLOBE NEWSWIRE) — 60 Degrees Pharmaceuticals, Inc. (NASDAQ: SXTP; SXTPW) (“60 Degrees Pharmaceuticals” or the “Company”), specialists in developing and marketing new medicines for the treatment and prevention of infectious diseases, announced today the pricing of its public offering |
|
| February 2, 2024 |
Exhibit 4.1 [FORM OF WARRANT] THE NUMBER OF SHARES OF COMMON STOCK ISSUABLE UPON EXERCISE OF THIS WARRANT MAY BE LESS THAN THE AMOUNTS SET FORTH ON THE FACE HEREOF PURSUANT TO SECTION 1(d) OF THIS WARRANT. 60 DEGREES PHARMACEUTICALS, INC. Non-tradeable Warrant To Purchase Common Stock Warrant No.: Date of Issuance: [●], 2024 (“Issuance Date”) 60 Degrees Pharmaceuticals, Inc., a Delaware corporatio |
|
| February 2, 2024 |
Exhibit 4.3 WARRANT AGENT AGREEMENT This Warrant Agent Agreement (this “Warrant Agreement”), effective as of January 31, 2024 (the “Issuance Date”) is between 60 Degrees Pharmaceuticals, Inc., a company incorporated under the laws of the State of Delaware (the “Company”), and Equity Stock Transfer, LLC, a Nevada limited liability company (the “Warrant Agent”). WHEREAS, pursuant to the terms of tha |
|
| February 2, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): January 29, 2024 60 DEGREES PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-41719 45-2406880 (State or other jurisdiction of Incorporation) ( |
|
| February 2, 2024 |
Exhibit 1.1 60 DEGREES PHARMACEUTICALS, INC. UNDERWRITING AGREEMENT 5,260,901 Units, Each Consisting of One Share of Common Stock and One Warrant to Purchase One Share of Common Stock; and 999,076 Pre-Funded Units, Each Consisting of One Pre-Funded Warrant to Purchase One Share of Common Stock and One Warrant to Purchase of One Share of Common Stock; and 6,259,977 of Common Shares Underlying the W |
|
| January 31, 2024 |
Filed Pursuant to Rule 424(b)(4) Registration No. 333-276641 5,260,901 Units, with each Unit consisting of One Share of Common Stock and One Warrant to Purchase One Share of Common Stock 999,076 Pre-Funded Units, with each Pre-Funded Unit consisting of One Pre-Funded Warrant to Purchase One Share of Common Stock and One Warrant to Purchase One Share of Common Stock 6,259,977 Shares of Common Stock |
|
| January 26, 2024 |
60 Degrees Pharmaceuticals, Inc. 1025 Connecticut Avenue NW, Suite 1000 Washington, DC 20036 60 Degrees Pharmaceuticals, Inc. 1025 Connecticut Avenue NW, Suite 1000 Washington, DC 20036 January 26, 2024 VIA EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Attention: Tyler Howes, Attorney Re: 60 Degrees Pharmaceuticals, Inc. Registration Statement on Form S-1 Initially Filed January 22, 2024 File No. 333-276641 Ladies a |
|
| January 26, 2024 |
60 Degrees Pharmaceuticals, Inc. 1025 Connecticut Avenue NW, Suite 1000 Washington, DC 20036 60 Degrees Pharmaceuticals, Inc. 1025 Connecticut Avenue NW, Suite 1000 Washington, DC 20036 January 26, 2024 VIA EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Attention: Tyler Howes, Attorney Re: 60 Degrees Pharmaceuticals, Inc. Request for Acceleration Registration Statement on Form S-1 File No. 333-276641 Ladies and Gentl |
|
| January 26, 2024 |
WallachBeth Capital LLC Harborside Financial Center Plaza 5 185 Hudson Street, Ste 1410 Jersey City, NJ 07311 VIA EDGAR January 26, 2024 United States Securities and Exchange Commission Division of Corporation Finance 100 F Street, N. |
|
| January 22, 2024 |
Exhibit 107 Calculation of Filing Fee Tables Form S-1 60 Degrees Pharmaceuticals, Inc. |
|
| January 22, 2024 |
WallachBeth Capital LLC Harborside Financial Center Plaza 5 185 Hudson Street, Ste 1410 Jersey City, NJ 07311 VIA EDGAR January 22, 2024 United States Securities and Exchange Commission Division of Corporation Finance 100 F Street, N. |
|
| January 22, 2024 |
Form of Pre-Funded Warrant in January 2024 public offering Exhibit 4.2 PRE-FUNDED COMMON STOCK PURCHASE WARRANT 60 DEGREES PHARMACEUTICALS, Inc. Warrant Shares: [●] Initial Exercise Date: [●] CUSIP: [●] Issue Date: [●] THIS PRE-FUNDED COMMON STOCK PURCHASE WARRANT (“Warrant”) certifies that, for value received, [●] or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, |
|
| January 22, 2024 |
Form of Warrant Agent Agreement in January 2024 public offering Exhibit 4.4 WARRANT AGENT AGREEMENT This Warrant Agent Agreement (this “Warrant Agreement”), effective as of [*], 2024 (the “Issuance Date”) is between 60 Degrees Pharmaceuticals, Inc., a company incorporated under the laws of the State of Delaware (the “Company”), and Equity Stock Transfer, LLC, a Nevada limited liability company (the “Warrant Agent”). WHEREAS, pursuant to the terms of that certa |
|
| January 22, 2024 |
60 Degrees Pharmaceuticals, Inc. 1025 Connecticut Avenue NW, Suite 1000 Washington, DC 20036 60 Degrees Pharmaceuticals, Inc. 1025 Connecticut Avenue NW, Suite 1000 Washington, DC 20036 January 22, 2024 VIA EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Re: 60 Degrees Pharmaceuticals, Inc. Request for Acceleration Registration Statement on Form S-1 File No. 333-276641 Ladies and Gentlemen: Pursuant to Rule 461 promul |
|
| January 22, 2024 |
Form of Representative Warrant in January 2024 public offering Exhibit 4.3 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933 (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTRATION STATEM |
|
| January 22, 2024 |
Exhibit 99.1 60 Degrees Pharma Plans Pivotal Babesiosis Study with Tafenoquine Following Jan 17 FDA Meeting January 22, 2024 12:59 PM EST ● Following a Type C meeting with FDA on January 17, 2024, 60 Degrees Pharma (60P) now plans to conduct a pivotal clinical study in support of a future indication for tafenoquine for treatment of hospitalized babesiosis patients ● Patient enrollment to begin in |
|
| January 22, 2024 |
Exhibit 4.1 [FORM OF WARRANT] THE NUMBER OF SHARES OF COMMON STOCK ISSUABLE UPON EXERCISE OF THIS WARRANT MAY BE LESS THAN THE AMOUNTS SET FORTH ON THE FACE HEREOF PURSUANT TO SECTION 1(d) OF THIS WARRANT. 60 DEGREES PHARMACEUTICALS, INC. Non-tradeable Warrant To Purchase Common Stock Warrant No.: Date of Issuance: [●], 2024 (“Issuance Date”) 60 Degrees Pharmaceuticals, Inc., a Delaware corporatio |
|
| January 22, 2024 |
As filed with the U.S. Securities and Exchange Commission on January 22, 2024. As filed with the U.S. Securities and Exchange Commission on January 22, 2024. Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 60 DEGREES PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 2834 45-2406880 (State or Other Jurisdiction of Incorporation or |
|
| January 22, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): January 22, 2024 60 DEGREES PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-41719 45-2406880 (State or other jurisdiction of Incorporation) ( |
|
| January 22, 2024 |
Form of Underwriting Agreement Exhibit 1.1 60 DEGREES PHARMACEUTICALS, INC. UNDERWRITING AGREEMENT [●] Units, Each Consisting of One Share of Common Stock and One Warrant to Purchase One Share of Common Stock; and [●] Pre-Funded Units, Each Consisting of One Pre-Funded Warrant to Purchase One Share of Common Stock and One Warrant to Purchase of One Share of Common Stock; and [●] Share of Common Stock Underlying the Warrants; an |
|
| January 16, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): January 10, 2024 60 DEGREES PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-41719 45-2406880 (State or other jurisdiction of Incorporation) ( |
|
| January 12, 2024 |
Draft Registration Statement on Form S-1 confidentially submitted to the U.S. Securities and Exchange Commission on January 12, 2024. This draft registration statement has not been filed, publicly or otherwise, with the U.S. Securities and Exchange Commission, and all information herein remains strictly confidential. Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington |
|
| December 18, 2023 |
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. -)* 60 Degrees Pharmaceuticals, Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 83006G104 (CUSIP Number) July 11, 2023 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pu |
|
| November 20, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 Form 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED SEPTEMBER 30, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM to COMMISSION FILE NUMBER 001-41719 60 DEG |
|
| November 15, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING (Check one): ☐ Form 10-K ☐ Form 20-F ☐ Form 11-K ☒ Form 10-Q ☐ Form 10-D ☐ Form N-CEN ☐ Form N-CSR For Period Ended: September 30, 2023 ☐ Transition Report on Form 10-K ☐ Transition Report on Form 20-F ☐ Transition Report on Form 11-K ☐ Transition Report on Form 10-Q For the Transition P |
|
| November 3, 2023 |
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): November 2, 2023 60 DEGREES PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-41719 45-2406880 (State or other jurisdiction of Incorporation) ( |
|
| October 12, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): October 6, 2023 60 DEGREES PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-41719 45-2406880 (State or other jurisdiction of Incorporation) (C |
|
| October 12, 2023 |
Exhibit 99.1 60 Degrees Pharmaceuticals Suspends Phase IIB Study of Tafenoquine for COVID-19, Pivots to Refocus on Commercialization of Treatments for Malaria and Tick-Borne Diseases ● FDA advice to the Company suggested execution of ACLR8-LR, a placebo-controlled Phase IIB study of tafenoquine in COVID-19 patients, may not be feasible in the U.S. ● The Company will therefore focus efforts on furt |
|
| September 18, 2023 |
Exhibit 99.1 60 Degrees Pharma Withdraws COVID Phase IIB IND, Will Resubmit Pending Assessment of Ability to Meet FDA Requirements ● Prompted by advice from FDA regarding study design, 60P Australia Pty Ltd, a majority-owned subsidiary of 60 Degrees Pharmaceuticals, has withdrawn its IND for ACLR8-LR, a Phase IIB study of the use of tafenoquine in treating COVID-19; Company plans to resubmit a rev |
|
| September 18, 2023 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): September 12, 2023 60 DEGREES PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-41719 45-2406880 (State or other jurisdiction of Incorporation) |
|
| August 25, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 Form 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED JUNE 30, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM to COMMISSION FILE NUMBER 001-41719 60 DEGREES |
|
| July 17, 2023 |
60 Degrees Pharmaceuticals Announces Pricing of Initial Public Offering Exhibit 99.1 60 Degrees Pharmaceuticals Announces Pricing of Initial Public Offering WASHINGTON, July 12, 2023 (GLOBE NEWSWIRE) - 60 Degrees Pharmaceuticals, Inc., (NASDAQ: SXTP; SXTPW) ("60P" or the "Company"), specialists in developing and marketing medicines for infectious diseases, announced today the pricing of its initial public offering of 1,415,095 units (each, a "Unit," collectively, the |
|
| July 17, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): July 12, 2023 60 DEGREES PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-41719 45-2406880 (State or other jurisdiction of Incorporation) (Com |
|
| July 17, 2023 |
Exhibit 4.3 WARRANT AGENT AGREEMENT This Warrant Agent Agreement (this “Warrant Agreement”), effective as of July 12, 2023 (the “Issuance Date”) is between 60 Degrees Pharmaceuticals, Inc., a company incorporated under the laws of the State of Delaware (the “Company”), and Equity Stock Transfer, LLC, a California limited liability company (the “Warrant Agent”). WHEREAS, pursuant to the terms of th |
|
| July 17, 2023 |
Exhibit 1.1 60 DEGREES PHARMACEUTICALS, INC. UNDERWRITING AGREEMENT 1,415,095 Units, Each Consisting of One Share of Common Stock, One Warrant to Purchase One Share of Common Stock, and One Non-tradeable Warrant to Purchase One Share of Common Stock July 12, 2023 WallachBeth Capital LLC Harborside Financial Center Plaza 5 185 Hudson Street, Ste 1410 Jersey City, NJ 07311 As Representative of the S |
|
| July 17, 2023 |
60 Degrees Pharmaceuticals Announces Closing of Initial Public Offering Exhibit 99.2 60 Degrees Pharmaceuticals Announces Closing of Initial Public Offering Washington DC, July 14, 2023 – 60 Degrees Pharmaceuticals, Inc., (NASDAQ: SXTP; SXTPW) (“60P” or the “Company”), specialists in developing and marketing medicines for infectious diseases, announced today the closing of its initial public offering of 1,415,095 units (each, a “Unit,” collectively, the “Units”) at a |
|
| July 17, 2023 |
Form of Non-tradeable Common Stock Purchase Warrant. Exhibit 4.2 THE NUMBER OF SHARES OF COMMON STOCK ISSUABLE UPON EXERCISE OF THIS WARRANT MAY BE LESS THAN THE AMOUNTS SET FORTH ON THE FACE HEREOF PURSUANT TO SECTION 1(d) OF THIS WARRANT. 60 DEGREES PHARMACEUTICALS, INC. Non-tradeable Warrant To Purchase Common Stock Warrant No.: 60 Degrees Pharmaceuticals, Inc., a Delaware corporation (the “Company”), hereby certifies that, for good and valuable |
|
| July 17, 2023 |
Representative Warrant dated as of July 14, 2023, issued by the Company to WallachBeth Capital LLC. Exhibit 4.4 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933 (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTRATION STATEM |
|
| July 17, 2023 |
Form of Tradeable Common Stock Purchase Warrant. Exhibit 4.1 60 DEGREES PHARMACEUTICALS, INC. COMMON STOCK PURCHASE WARRANT Warrant Shares: THIS COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the date the Common Stock of the Company (as defined be |
|
| July 13, 2023 |
Filed Pursuant to Rule 424(b)(4) Registration No. 333-269483 1,415,095 Units Each Unit Consisting of One Share of Common Stock, One Warrant to Purchase One share of Common Stock, and One Non-tradeable Warrant to Purchase One Share of Common Stock and the 2,830,190 Shares of Common Stock underlying such Warrants 60 Degrees Pharmaceuticals, Inc. This is a firm commitment initial public offering of 1 |
|
| July 7, 2023 |
60 Degrees Pharmaceuticals, Inc. 1025 Connecticut Avenue NW Suite 1000 Washington, D.C. 20036 60 Degrees Pharmaceuticals, Inc. 1025 Connecticut Avenue NW Suite 1000 Washington, D.C. 20036 July 7, 2023 VIA EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences 100 F Street, N.E. Washington, D.C. 20549 Attn: Mr. Joshua Gorsky / Mr. Tim Buchmiller Re: 60 Degrees Pharmaceuticals, Inc. Registration Statement on Form S-1, as amended Initially Filed |
|
| July 7, 2023 |
WallachBeth Capital LLC Harborside Financial Center Plaza 5 185 Hudson Street, Ste 1410 Jersey City, NJ 07311 VIA EDGAR July 7, 2023 United States Securities and Exchange Commission Division of Corporation Finance 100 F Street, N. |
|
| June 27, 2023 |
60 Degrees Pharmaceuticals, Inc. 1025 Connecticut Avenue NW Suite 1000 Washington, D.C. 20036 60 Degrees Pharmaceuticals, Inc. 1025 Connecticut Avenue NW Suite 1000 Washington, D.C. 20036 June 27, 2023 VIA EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences 100 F Street, N.E. Washington, D.C. 20549 Attn: Mr. Joshua Gorsky / Mr. Tim Buchmiller Re: 60 Degrees Pharmaceuticals, Inc. Registration Statement on Form S-1, as amended Initially Filed |
|
| June 27, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Amendment No. 2 to FORM 8-A FOR REGISTRATION OF CERTAIN CLASSES OF SECURITIES PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 60 Degrees Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 45-2406880 (State or other jurisdiction of incorporation) (IRS Employer Identific |
|
| June 27, 2023 |
60 Degrees Pharmaceuticals, Inc. 1025 Connecticut Avenue NW Suite 1000 Washington, D.C. 20036 60 Degrees Pharmaceuticals, Inc. 1025 Connecticut Avenue NW Suite 1000 Washington, D.C. 20036 June 27, 2023 VIA EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Attention: Tim Buchmiller, Senior Attorney Joshua Gorsky, Attorney Adviser Re: 60 Degrees Pharmaceuticals, Inc. Registration Statement on Form S-1, as amended Initially |
|
| June 27, 2023 |
WallachBeth Capital LLC Harborside Financial Center Plaza 5 185 Hudson Street, Ste 1410 Jersey City, NJ 07311 VIA EDGAR June 27, 2023 United States Securities and Exchange Commission Division of Corporation Finance 100 F Street, N. |
|
| June 22, 2023 |
60 Degrees Pharmaceuticals, Inc. 1025 Connecticut Avenue NW Suite 1000 Washington, D.C. 20036 60 Degrees Pharmaceuticals, Inc. 1025 Connecticut Avenue NW Suite 1000 Washington, D.C. 20036 June 22, 2023 VIA EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Attention: Tim Buchmiller, Senior Attorney Joshua Gorsky, Attorney Adviser Re: 60 Degrees Pharmaceuticals, Inc. Registration Statement on Form S-1, as amended Initially |
|
| June 16, 2023 |
60 Degrees Pharmaceuticals, Inc. 1025 Connecticut Avenue NW Suite 1000 Washington, D.C. 20036 60 Degrees Pharmaceuticals, Inc. 1025 Connecticut Avenue NW Suite 1000 Washington, D.C. 20036 June 16, 2023 VIA EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences 100 F Street, N.E. Washington, D.C. 20549 Attn: Mr. Joshua Gorsky / Mr. Tim Buchmiller Re: 60 Degrees Pharmaceuticals, Inc. Registration Statement on Form S-1, as amended Initially Filed |
|
| June 16, 2023 |
WallachBeth Capital LLC Harborside Financial Center Plaza 5 185 Hudson Street, Ste 1410 Jersey City, NJ 07311 VIA EDGAR June 16, 2023 United States Securities and Exchange Commission Division of Corporation Finance 100 F Street, N. |
|
| June 14, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-A FOR REGISTRATION OF CERTAIN CLASSES OF SECURITIES PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 60 Degrees Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 45-2406880 (State or other jurisdiction of incorporation) (IRS Employer Identification Number) 1025 |
|
| June 14, 2023 |
60 Degrees Pharmaceuticals, Inc. 1025 Connecticut Avenue NW Suite 1000 Washington, D.C. 20036 60 Degrees Pharmaceuticals, Inc. 1025 Connecticut Avenue NW Suite 1000 Washington, D.C. 20036 June 14, 2023 VIA EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Attention: Tim Buchmiller, Senior Attorney Joshua Gorsky, Attorney Adviser Re: 60 Degrees Pharmaceuticals, Inc. Registration Statement on Form S-1, as amended Initially |
|
| June 14, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Amendment No. 1 to FORM 8-A FOR REGISTRATION OF CERTAIN CLASSES OF SECURITIES PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 60 Degrees Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 45-2406880 (State or other jurisdiction of incorporation) (IRS Employer Identific |
|
| June 12, 2023 |
60 Degrees Pharmaceuticals, Inc. 1025 Connecticut Avenue NW Suite 1000 Washington, D.C. 20036 60 Degrees Pharmaceuticals, Inc. 1025 Connecticut Avenue NW Suite 1000 Washington, D.C. 20036 June 12, 2023 VIA EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences 100 F Street, N.E. Washington, D.C. 20549 Attn: Mr. Joshua Gorsky / Mr. Tim Buchmiller Re: 60 Degrees Pharmaceuticals, Inc. Registration Statement on Form S-1, as amended Initially Filed |
|
| June 12, 2023 |
WallachBeth Capital LLC Harborside Financial Center Plaza 5 185 Hudson Street, Ste 1410 Jersey City, NJ 07311 VIA EDGAR June 12, 2023 United States Securities and Exchange Commission Division of Corporation Finance 100 F Street, N. |
|
| June 8, 2023 |
Exhibit 10.57 60 DEGREES PHARMACEUTICALS INC BOARD OF DIRECTORS AGREEMENT This BOARD OF DIRECTORS AGREEMENT (“Agreement”) dated as of November 28th, 2022, by and between 60 DEGREES PHARMACEUTICALS, INC, a Delaware corporation (the “Company”), and the undersigned signatory (the “Director”), provides for director services, according to the following terms and conditions: I. Position and Responsibili |
|
| June 8, 2023 |
Exhibit 10.58 60 DEGREES PHARMACEUTICALS INC BOARD OF DIRECTORS AGREEMENT This BOARD OF DIRECTORS AGREEMENT (“Agreement”) dated as of November 28th, 2022, by and between 60 DEGREES PHARMACEUTICALS, INC, a Delaware corporation (the “Company”), and the undersigned signatory (the “Director”), provides for director services, according to the following terms and conditions: I. Position and Responsibili |
|
| June 8, 2023 |
As filed with the U.S. Securities and Exchange Commission on June 8, 2023 As filed with the U.S. Securities and Exchange Commission on June 8, 2023 Registration No. 333-269483 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Amendment No. 5 to FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 60 DEGREES PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 2834 45-2406880 (State or Other Jurisdiction |
|
| June 8, 2023 |
Exhibit 10.59 60 DEGREES PHARMACEUTICALS INC BOARD OF DIRECTORS AGREEMENT This BOARD OF DIRECTORS AGREEMENT (“Agreement”) dated as of December 9, 2022, by and between 60 DEGREES PHARMACEUTICALS, INC, a Delaware corporation (the “Company”), and the undersigned signatory (the “Director”), provides for director services, according to the following terms and conditions: I. Position and Responsibilitie |
|
| June 8, 2023 |
June 8, 2023 Via EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences 100 F Street, N.E. Washington, D.C. 20549 Attn: Mr. Franklin Wyman, Mr. Kevin Kuhar, Mr. Joshua Gorsky and Mr. Tim Buchmiller Re: 60 Degrees Pharmaceuticals, Inc. Amendment No. 4 to Form S-1 CIK No. 0001946563 Dear Mr. Wyman, Mr. Kuhar, Mr. Gorsky and Mr. Buchmiller: On behalf of |
|
| June 8, 2023 |
Exhibit 10.56 60 DEGREES PHARMACEUTICALS INC BOARD OF DIRECTORS AGREEMENT This BOARD OF DIRECTORS AGREEMENT (“Agreement”) dated as of December 15, 2022, by and between 60 DEGREES PHARMACEUTICALS, INC, a Delaware corporation (the “Company”), and the undersigned signatory (the “Director”), provides for director services, according to the following terms and conditions: I. Position and Responsibiliti |
|
| June 8, 2023 |
Form of Underwriting Agreement Exhibit 1.1 60 DEGREES PHARMACEUTICALS, INC. UNDERWRITING AGREEMENT [●] Units, Each Consisting of One Share of Common Stock, One Warrant to Purchase One Share of Common Stock, and One Non-tradeable Warrant to Purchase One Share of Common Stock [●], 2023 WallachBeth Capital LLC Harborside Financial Center Plaza 5 185 Hudson Street, Ste 1410 Jersey City, NJ 07311 As Representative of the Several Und |
|
| June 1, 2023 |
Exhibit 10.53 NOTE EXTENSION AGREEMENT THIS NOTE EXTENSION AGREEMENT (this “Agreement”) is entered into and made effective as of May 22, 2023, by and between 60 DEGREES PHARMACEUTICALS, INC., a Delaware corporation (the “Maker”) and CAVALRY INVESTMENT FUND, L.P. (the “Holder”). WHEREAS, the Maker and the Holder entered into that certain Promissory Note dated as of May 24, 2022 for the amount of Tw |
|
| June 1, 2023 |
Form of Common Stock Purchase Warrant to be issued by the Registrant to WallachBeth Capital LLC Exhibit 10.51 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933 (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTRATION STAT |
|
| June 1, 2023 |
As filed with the U.S. Securities and Exchange Commission on June 1, 2023 As filed with the U.S. Securities and Exchange Commission on June 1, 2023 Registration No. 333-269483 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Amendment No. 4 to FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 60 DEGREES PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 2834 45-2406880 (State or Other Jurisdiction |
|
| June 1, 2023 |
Form of Underwriting Agreement Exhibit 1.1 60 DEGREES PHARMACEUTICALS, INC. UNDERWRITING AGREEMENT [●] Units, Each Consisting of One Share of Common Stock, One Warrant to Purchase One Share of Common Stock, and One Non-tradeable Warrant to Purchase One Share of Common Stock [●], 2023 WallachBeth Capital LLC Harborside Financial Center Plaza 5 185 Hudson Street, Ste 1410 Jersey City, NJ 07311 As Representative of the Several Und |
|
| June 1, 2023 |
Exhibit 10.54 NOTE EXTENSION AGREEMENT THIS NOTE EXTENSION AGREEMENT (this “Agreement”) is entered into and made effective as of May 22, 2023, by and between 60 DEGREES PHARMACEUTICALS, INC., a Delaware corporation (the “Maker”) and WALLEYE OPPORTUNITIES MASTER FUND LTD. (the “Holder”). WHEREAS, the Maker and the Holder entered into that certain Promissory Note dated as of May 24, 2022 for the amo |
|
| June 1, 2023 |
Exhibit 10.43 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933 (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTRATION STAT |
|
| June 1, 2023 |
Exhibit 10.52 NOTE EXTENSION AGREEMENT THIS NOTE EXTENSION AGREEMENT (this “Agreement”) is entered into and made effective as of May 22, 2023, by and between 60 DEGREES PHARMACEUTICALS, INC., a Delaware corporation (the “Maker”) and BIGGER CAPITAL FUND, L.P. (the “Holder”). WHEREAS, the Maker and the Holder entered into that certain Promissory Note dated as of May 24, 2022 for the amount of Three |
|
| June 1, 2023 |
June 1, 2023 Via EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences 100 F Street, N.E. Washington, D.C. 20549 Attn: Mr. Franklin Wyman, Mr. Kevin Kuhar, Mr. Joshua Gorsky and Mr. Tim Buchmiller Re: 60 Degrees Pharmaceuticals, Inc. Amendment No. 3 to Form S-1 CIK No. 0001946563 Dear Mr. Wyman, Mr. Kuhar, Mr. Gorsky and Mr. Buchmiller: On behalf of |
|
| June 1, 2023 |
Note Extension Agreement dated as of May 18, 2023, by and between the Registrant and Mountjoy Trust Exhibit 10.56 NOTE EXTENSION AGREEMENT THIS NOTE EXTENSION AGREEMENT (this “Agreement”) is entered into and made effective as of May 18, 2023, by and between 60 DEGREES PHARMACEUTICALS, INC., a Delaware corporation (the “Maker”) and MOUNTJOY TRUST (the “Holder”). WHEREAS, the Maker and the Holder entered into that certain Promissory Note dated as of May 19, 2022 for the amount of Two Hundred Ninet |
|
| June 1, 2023 |
Exhibit 10.55 NOTE EXTENSION AGREEMENT THIS NOTE EXTENSION AGREEMENT (this “Agreement”) is entered into and made effective as of May 18, 2023, by and between 60 DEGREES PHARMACEUTICALS, INC., a Delaware corporation (the “Maker”) and GEOFFREY S. DOW REVOCABLE TRUST (the “Holder”). WHEREAS, the Maker and the Holder entered into that certain Promissory Note dated as of May 19, 2022 for the amount of |
|
| May 19, 2023 |
Exhibit 10.39 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”) is dated as of May 8, 2023, by and between 60° Pharmaceuticals, Inc, and each investor that executes the signature page hereto as a purchaser (each, a “Purchaser” and collectively, the “Purchasers”). WHEREAS, subject to the terms and conditions set forth in this Agreement and pursuant to an exemption |
|
| May 19, 2023 |
Exhibit 107 Calculation of Filing Fee Tables Form S-1 60 Degrees Pharmaceuticals, Inc. |
|
| May 19, 2023 |
Promissory Note dated as of May 8, 2023, issued by the Registrant to Bixi Gao & Ling Ling Wang Exhibit 10.50 NEITHER THIS SECURITY NOR THE SECURITIES INTO WHICH THIS SECURITY IS CONVERTIBLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGI |
|
| May 19, 2023 |
Common Stock Purchase Warrant dated as of May 8, 2023, issued by the Registrant to Steel Anderson Exhibit 10.46 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933 (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTRATION STAT |
|
| May 19, 2023 |
Exhibit 10.42 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”) is dated as of May 8, 2023, by and between 60° Pharmaceuticals, Inc, and each investor that executes the signature page hereto as a purchaser (each, a “Purchaser” and collectively, the “Purchasers”). WHEREAS, subject to the terms and conditions set forth in this Agreement and pursuant to an exemption |
|
| May 19, 2023 |
Promissory Note dated as of May 8, 2023, issued by the Registrant to Ariana Bakery Inc Exhibit 10.41 NEITHER THIS SECURITY NOR THE SECURITIES INTO WHICH THIS SECURITY IS CONVERTIBLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGI |
|
| May 19, 2023 |
Securities Purchase Agreement dated as of May 8, 2023, by and between Registrant and Steel Anderson Exhibit 10.45 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”) is dated as of May 8, 2023, by and between 60° Pharmaceuticals, Inc, and each investor that executes the signature page hereto as a purchaser (each, a “Purchaser” and collectively, the “Purchasers”). WHEREAS, subject to the terms and conditions set forth in this Agreement and pursuant to an exemption |
|
| May 19, 2023 |
Exhibit 10.48 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”) is dated as of May 8, 2023, by and between 60° Pharmaceuticals, Inc, and each investor that executes the signature page hereto as a purchaser (each, a “Purchaser” and collectively, the “Purchasers”). WHEREAS, subject to the terms and conditions set forth in this Agreement and pursuant to an exemption |
|
| May 19, 2023 |
Exhibit 10.37 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933 (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTRATION STAT |
|
| May 19, 2023 |
Promissory Note dated as of May 8, 2023, issued by the Registrant to Steel Anderson Exhibit 10.47 NEITHER THIS SECURITY NOR THE SECURITIES INTO WHICH THIS SECURITY IS CONVERTIBLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGI |
|
| May 19, 2023 |
Exhibit 10.43 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933 (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTRATION STAT |
|
| May 19, 2023 |
May 19, 2023 Via EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences 100 F Street, N.E. Washington, D.C. 20549 Attn: Mr. Franklin Wyman, Mr. Kevin Kuhar, Mr. Joshua Gorsky and Mr. Tim Buchmiller Re: 60 Degrees Pharmaceuticals, Inc. Amendment No. 2 to Form S-1 CIK No. 0001946563 Dear Mr. Wyman, Mr. Kuhar, Mr. Gorsky and Mr. Buchmiller: On behalf of |
|
| May 19, 2023 |
Exhibit 10.36 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”) is dated as of May 8, 2023, by and between 60° Pharmaceuticals, Inc, and each investor that executes the signature page hereto as a purchaser (each, a “Purchaser” and collectively, the “Purchasers”). WHEREAS, subject to the terms and conditions set forth in this Agreement and pursuant to an exemption |
|
| May 19, 2023 |
Exhibit 10.38 NEITHER THIS SECURITY NOR THE SECURITIES INTO WHICH THIS SECURITY IS CONVERTIBLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGI |
|
| May 19, 2023 |
Exhibit 10.49 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933 (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTRATION STAT |
|
| May 19, 2023 |
As filed with the U.S. Securities and Exchange Commission on May 19, 2023 As filed with the U.S. Securities and Exchange Commission on May 19, 2023 Registration No. 333-269483 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Amendment No. 3 to FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 60 DEGREES PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 2834 45-2406880 (State or Other Jurisdiction |
|
| May 19, 2023 |
Exhibit 10.44 NEITHER THIS SECURITY NOR THE SECURITIES INTO WHICH THIS SECURITY IS CONVERTIBLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGI |
|
| May 19, 2023 |
Common Stock Purchase Warrant dated as of May 8, 2023, issued by the Registrant to Ariana Bakery Inc Exhibit 10.40 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933 (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTRATION STAT |
|
| April 28, 2023 |
Exhibit 10.33 AGREEMENT and PLAN OF MERGER of 60 DEGREES PHARMACEUTICALS, LLC This Agreement and Plan of Merger (the “Plan”) for 60 Degrees Pharmaceuticals, LLC, a District of Columbia limited liability company (the “Company”), is made and entered into effective as of June 1, 2022 in accordance with the terms of the Company’s Eighth Amended and Restated Operating Agreement, dated as of December 31 |
|
| April 28, 2023 |
Consent of Director Nominee of Charles Allen Exhibit 99.1 Consent of Director Nominee 60 Degrees Pharmaceuticals, Inc. is filing a Registration Statement on Form S-1 (Registration No. 333-269483) with the Securities and Exchange Commission under the Securities Act of 1933, as amended (the “Securities Act”), in connection with the initial public offering of common stock of 60 Degrees Pharmaceuticals, Inc. In connection therewith, I hereby con |
|
| April 28, 2023 |
Form of Representative Warrant Exhibit 4.3 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933 (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTRATION STATEM |
|
| April 28, 2023 |
Common Stock Purchase Warrant dated as of May 19, 2022, issued by the Registrant to Mountjoy Trust Exhibit 10.5 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933 (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTRATION STATE |
|
| April 28, 2023 |
Exhibit 10.32 AGREEMENT TO CONVERT DEBT TO EQUITY This Agreement to Convert Debt to Equity (the “Agreement”) is made as of the 3lst day of August, 2021 between 60° Pharmaceuticals, LLC, a limited liability company organized and operating under the laws of Washington, District of Columbia ( “Company"), and Dong Loock (“Creditor"), as follows: A. Creditor has loaned US S32,000 (the "Debt") to Compan |
|
| April 28, 2023 |
Employment Agreement dated as of January 12, 2023, between the Registrant and Geoffrey Dow Exhibit 10.22 EMPLOYMENT AGREEMENT This Employment Agreement, dated as of January 12, 2023 (this “Agreement”), is made and entered into by and between 60 Degrees Pharmaceuticals Inc., a De corporation (the “Company”), and Geoffrey Dow (the “Executive” and together with the Company, the “Parties” and individually a “Party”). Capitalized terms used herein and not otherwise defined shall have the mea |
|
| April 28, 2023 |
Exhibit 10.15 EXHIBIT A NEITHER THIS SECURITY NOR THE SECURITIES INTO WHICH THIS SECURITY IS CONVERTIBLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFE |
|
| April 28, 2023 |
As filed with the U.S. Securities and Exchange Commission on April 28, 2023 As filed with the U.S. Securities and Exchange Commission on April 28, 2023 Registration No. 333-269483 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Amendment No. 2 to FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 60 DEGREES PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 2834 45-2406880 (State or Other Jurisdictio |
|
| April 28, 2023 |
Exhibit 4.4 FORM OF WARRANT AGENT AGREEMENT This Warrant Agent Agreement (this “Warrant Agreement”), dated as of [●], 2023 (the “Issuance Date”) is between 60 Degrees Pharmaceuticals, Inc., a company incorporated under the laws of the State of Delaware (the “Company”), and Equity Stock Transfer, LLC, a California limited liability company (the “Warrant Agent”). WHEREAS, pursuant to the terms of th |
|
| April 28, 2023 |
Exhibit 10.24 Please be advised that certain identified information has been excluded in Exhibit 10.24 because it is the type of information that the registrant treats as private or confidential and is (i) not material and (ii) would be competitively harmful if publicly disclosed. 600 PHARMACEUTICALS,LLC SUBSCRIPTION AGREEMENT WITH Avante International Limited October 11, 2017 NOTICE TO INVESTORS |
|
| April 28, 2023 |
Compensation Committee Charter Exhibit 99.6 COMPENSATION COMMITTEE CHARTER OF 60 DEGREES PHARMACEUTICALS, INC. I. Adoption of Charter The Board of Directors (the “Board”) of 60 Degrees Pharmaceuticals, Inc., a Delaware corporation (the “Corporation”), has adopted this Charter of the Compensation Committee (this “Charter”) of the Board (the “Committee”). II. Organization 1. Committee Structure and Membership. The Committee shall |
|
| April 28, 2023 |
Exhibit 10.35 60 DEGREES PHARMACEUTICALS, INC. 2022 EQUITY INCENTIVE PLAN 1. Purposes of the Plan. The purposes of this Plan are: · to attract and retain the best available personnel for positions of substantial responsibility, · to provide additional incentive to Employees, Directors and Consultants, and · to promote the success of the Company’s business. The Plan permits the grant of Incentive S |
|
| April 28, 2023 |
Exhibit 10.25 Please be advised that certain identified information has been excluded in Exhibit 10.25 because it is the type of information that the registrant treats as private or confidential and is (i) not material and (ii) would be competitively harmful if publicly disclosed. THE NOTE REPRESENTED HEREBY HAS NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933,AS AMENDED, ANO MAY NOT BE SOLO, |
|
| April 28, 2023 |
Exhibit 10.18 Please be advised that certain identified information has been excluded in Exhibit 10.18 because it is the type of information that the registrant treats as private or confidential and is (i) not material and (ii) would be competitively harmful if publicly disclosed. AMMENDMENT TWO TO THE DEBT CONVERSION AGREEMENT This second amendment to the Debt Conversion Agreement (the “Second Am |
|
| April 28, 2023 |
Exhibit 10.16 Please be advised that certain identified information has been excluded in Exhibit 10.16 because it is the type of information that the registrant treats as private or confidential and is (i) not material and (ii) would be competitively harmful if publicly disclosed. DEBT CONVERSION AGREEMENT This Debt Conversion Agreement (the “Agreement”), dated as of January 9, 2023, is by and bet |
|
| April 28, 2023 |
Promissory Note dated as of May 24, 2022, issued by the Registrant to Cavalry Investment Fund, LP Exhibit 10.12 EXHIBIT A NEITHER THIS SECURITY NOR THE SECURITIES INTO WHICH THIS SECURITY IS CONVERTIBLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFE |
|
| April 28, 2023 |
Nominating and Corporate Governance Committee Charter Exhibit 99.7 NOMINATING AND CORPORATE GOVERNANCE COMMITTEE CHARTER OF 60 DEGREES PHARMACEUTICALS, INC. I. Adoption of Charter The Board of Directors (the “Board”) of 60 Degrees Pharmaceuticals, Inc., a Delaware corporation (the “Corporation”), has adopted this Charter of the Nominating and Corporate Governance Committee (this “Charter”) of the Board (the “Committee”). II. Organization 1. Committee |
|
| April 28, 2023 |
Consent of Director Nominee of Cheryl Xu Exhibit 99.2 Consent of Director Nominee 60 Degrees Pharmaceuticals, Inc. is filing a Registration Statement on Form S-1 (Registration No. 333-269483) with the Securities and Exchange Commission under the Securities Act of 1933, as amended (the “Securities Act”), in connection with the initial public offering of common stock of 60 Degrees Pharmaceuticals, Inc. In connection therewith, I hereby con |
|
| April 28, 2023 |
Exhibit 10.8 EXHIBIT B NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933 (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTRA |
|
| April 28, 2023 |
Convertible Promissory Note dated as of May 19, 2022, issued by the Registrant to Mountjoy Trust Exhibit 10.6 NEITHER THIS SECURITY NOR THE SECURITIES INTO WHICH THIS SECURITY IS CONVERTIBLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGIS |
|
| April 28, 2023 |
Consent of Director Nominee of Paul Field Exhibit 99.4 Consent of Director Nominee 60 Degrees Pharmaceuticals, Inc. is filing a Registration Statement on Form S-1 (Registration No. 333-269483) with the Securities and Exchange Commission under the Securities Act of 1933, as amended (the “Securities Act”), in connection with the initial public offering of common stock of 60 Degrees Pharmaceuticals, Inc. In connection therewith, I hereby con |
|
| April 28, 2023 |
Exhibit 4.2 [FORM OF NON-TRADEABLE WARRANT] THE NUMBER OF SHARES OF COMMON STOCK ISSUABLE UPON EXERCISE OF THIS WARRANT MAY BE LESS THAN THE AMOUNTS SET FORTH ON THE FACE HEREOF PURSUANT TO SECTION 1(d) OF THIS WARRANT. 60 DEGREES PHARMACEUTICALS, INC. Non-tradeable Warrant To Purchase Common Stock Warrant No.: Date of Issuance: [●], 2023 (“Issuance Date”) 60 Degrees Pharmaceuticals, Inc., a Delaw |
|
| April 28, 2023 |
Amended and Restated Bylaws of the Registrant Exhibit 3.4 AMENDED AND RESTATED BYLAWS OF 60 DEGREES PHARMACEUTICALS, INC. (A DELAWARE CORPORATION) ARTICLE I OFFICES Section 1.1 Registered Office. The registered office of the corporation in the State of Delaware is 251 Little Falls Drive, Wilmington, Delaware 19808 or in such other location as the Board of Directors of the corporation (the “Board of Directors”) may from time to time determine |
|
| April 28, 2023 |
List of Subsidiaries of the Registrant Exhibit 21.1 List of Subsidiaries of 60 Degrees Pharmaceuticals, Inc. Name of Subsidiary Jurisdiction of Organization 60 Degrees Pharmaceuticals, LLC District of Columbia 60P Australia Pty Ltd Australia 60P Singapore PTE, LTD Singapore |
|
| April 28, 2023 |
Convertible Promissory Note dated as of December 31, 2016, issued by the Registrant to Geoffrey Dow Exhibit 10.26 Please be advised that certain identified information has been excluded in Exhibit 10.26 because it is the type of information that the registrant treats as private or confidential and is (i) not material and (ii) would be competitively harmful if publicly disclosed. CONVERTIBLE PROMISSORY NOTE Original Issue Date: December 31st 2016 Principal Amount: $ 346,000.00 USD FOR VALUE RECEI |
|
| April 28, 2023 |
Exhibit 10.2 Please be advised that certain identified information has been excluded in Exhibit 10.2 because it is the type of information that the registrant treats as private or confidential and is (i) not material and (ii) would be competitively harmful if publicly disclosed. NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES |
|
| April 28, 2023 |
Certificate of Correction to Certificate of Incorporation of the Registrant Exhibit 3.3 Delaware The First State Page 1 I, JEFFREY W. BULLOCK, SECRETARY OF STATE OF THE STATE OF DELAWARE, DO HEREBY CERTIFY THE ATTACHED IS A TRUE AND CORRECT COPY OF THE CORRECTED CERTIFICATE OF “60 DEGREES PHARMACEUTICALS, INC.”, FILED IN THIS OFFICE ON NINETEENTH DAY OF APRIL, A.D. 2023, AT 12:24 O`CLOCK P.M. 6829222 8100 SR# 20231519698 Authentication: 203172061 Date: 04-19-23 You may ve |
|
| April 28, 2023 |
Exhibit 10.30 Please be advised that certain identified information has been excluded in Exhibit 10.30 because it is the type of information that the registrant treats as private or confidential and is (i) not material and (ii) would be competitively harmful if publicly disclosed. AGREEMENT TO CONVERT DEBT TO EQUITY This Agreement to Convert Debt to Equity (the “Agreement”) is made effective as of |
|
| April 28, 2023 |
Exhibit 10.17 Please be advised that certain identified information has been excluded in Exhibit 10.17 because it is the type of information that the registrant treats as private or confidential and is (i) not material and (ii) would be competitively harmful if publicly disclosed. AMMENDMENT TO THE DEBT CONVERSION AGREEMENT This amendment to the Debt Conversion Agreement (the “Amendment Agreement” |
|
| April 28, 2023 |
Exhibit 10.14 EXHIBIT B NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933 (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTR |
|
| April 28, 2023 |
Exhibit 10.10 Please be advised that certain identified information has been excluded in Exhibit 10.10 because it is the type of information that the registrant treats as private or confidential and is (i) not material and (ii) would be competitively harmful if publicly disclosed. SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”) is dated as of May 24, 2022, by an |
|
| April 28, 2023 |
Certificate of Incorporation of the Registrant Exhibit 3.1 Delaware Page 1 The First State I, JEFFREY W. BULLOCK, SECRETARY OF STATE OF THE STATE OF DELAWARE, DO HEREBY CERTIFY THE ATTACHED IS A TRUE AND CORRECT COPY OF THE CERTIFICATE OF INCORPORATION OF “60 DEGREES PHARMACEUTICALS, INC.", FILED IN THIS OFFICE ON THE FIRST DAY OF JUNE, A.D. 2022, AT 8 O'CLOCK A.M. /s/ Jeffrey W. Bullock Jeffrey W. Bullock, Secretary Of State 6829222 8100 SR# |
|
| April 28, 2023 |
Exhibit 10.34 Please be advised that certain identified information has been excluded in Exhibit 10.34 because it is the type of information that the registrant treats as private or confidential and is (i) not material and (ii) would be competitively harmful if publicly disclosed. CONFIDENTIAL EXCLUSIVE LICENSE AGREEMENT This EXCLUSIVE LICENSE AGREEMENT ("Agreement") is made on the 30th day of May |
|
| April 28, 2023 |
Convertible Promissory Note dated as of May 19, 2022, issued by the Registrant to Geoffrey Dow Exhibit 10.3 Please be advised that certain identified information has been excluded in Exhibit 10.3 because it is the type of information that the registrant treats as private or confidential and is (i) not material and (ii) would be competitively harmful if publicly disclosed. NEITHER THIS SECURITY NOR THE SECURITIES INTO WHICH THIS SECURITY IS CONVERTIBLE HAVE BEEN REGISTERED WITH THE SECURITIE |
|
| April 28, 2023 |
Employment Agreement dated as of January 12, 2023, between the Registrant and Tyrone Miller Exhibit 10.23 EMPLOYMENT AGREEMENT This Employment Agreement, dated as of January 12, 2023 (this “Agreement”), is made and entered into by and between 60 Degrees Pharmaceuticals Inc., a Delaware corporation (the “Company”), and Tyrone Miller (the “Executive” and together with the Company, the “Parties” and individually a “Party”). Capitalized terms used herein and not otherwise defined shall have |
